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Abstract 
The purpose of these studies was to develop Raman spectroscopic techniques to 
support in situ cancer diagnosis during endoscopic observation. Reliable diagnostic 
techniques are essential for cancer diagnosis, which may reduce invasiveness and provide 
objective data, thus improving the accuracy of endoscopic diagnosis.  
The aim of the first study was to evaluate the capability of a miniaturized Raman 
endoscope (mRE) system to monitor the advancement in colorectal tumors in a mouse 
model. The endoscope was narrow enough to observe the internal portion of the mouse 
colon in a semi-noninvasive method, following anesthesia treatment. The mRE system 
allowed the visualization and Raman spectral measurement of any targeted point within 
the colorectal tumor in the model animal under anesthesia, with no damage to the tissue 
(i.e., noninvasive method). Continuous monitoring of the same tumor allowed 
observation of the alteration in its molecular composition and size, as well as the tumor 
advancement. The tumor lesion was distinguished from the normal tissues of the control 
mouse at an accuracy of 86.8%. The Raman spectra obtained from the live mouse colon 
revealed molecular changes in lipid and protein profiles. As the next step, it would be 
necessary to evaluate the effectiveness of the mRE system.  
In the second study, the effects of anticancer drugs were studied using the mRE 
system in the mouse model. Three anticancer drugs, 5-fluorouracil (5-FU), cisplatin 
(CDDP), and docetaxel were employed for this purpose. This study demonstrated that in 
situ Raman analysis is highly sensitive in detecting the effects of anticancer drugs. On the 
other hand, a noninvasive technique was developed to collect images, as one of the 
standards for diagnosis.  
The third study investigated the site dependency in cancer tissue using unstained 
  
autofluorescence hyperspectral imaging (AF-HSI) and Raman spectroscopy. AF-HSI 
images reflected the distribution of intact fluorescence materials such as nicotinamide 
adenine dinucleotide (NADH), flavin adenine dinucleotide (FAD), and collagen in the 
subcutaneous tumor in a live mouse model. Raman spectroscopy showed the difference 
in blood flow between the active and non-active areas with NADH imaging. AF-HSI 
image in situ and Raman spectroscopy revealed the distribution of collagen type I. AF-
HSI images gathered information that was inaccessible using tissue sections. The 
measurement methods using the mouse model, Raman spectroscopy, and 
autofluorescence imaging were important tools to study cancer progression and 
anticancer drug treatment. 
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General Introduction 
Colorectal cancer is the most common cause of cancer deaths in women and the 
third most common cause of cancer deaths in men in Japan1. In Japan, colon examination 
is conducted through screening tests for the early detection and diagnosis of colorectal 
cancer. Patients are diagnosed with other methods upon detection of blood in the stool. A 
blood test is generally the second preferred method for the detection of cancer markers 
and may be the most convenient method with less impact on the patient’s health2. 
Precision examination is performed after the blood test. Endoscope test and 
histopathology using tissue biopsy are standard methods that directly analyze lesions in 
the colon3. The reliability of endoscopic observations largely depends on the knowledge 
and skill of the clinicians. J. C. Rijn reported a global miss rate of 21% in the detection 
of colorectal polyps with endoscopy4. This report is expected to improve the accuracy of 
the endoscopic diagnosis. Some additional techniques have been developed to allow 
visualization of the fine texture of the tissue surface during endoscopy, such as spraying 
indigo carmine dye, narrow band imaging observation, and auto-fluorescence imaging5-7. 
Cancer diagnosis based on visual observation fully relies on the pattern recognition ability 
or “esthetic eyes'” of clinicians. In addition to the direct observation of colorectal cancer 
with an endoscope, a few methods that allow cancer detection in a completely 
noninvasive manner include X-ray computed tomography (X-CT), magnetic resonance 
imaging (MRI), and positron emission tomography (PET), which allow visualization of 
the tumor shape8-10. Although the accuracy of diagnosis by X-CT, MRI, and PET is 
increasing every year, the results may not be convincing enough for the clinicians. As X-
ray CT poses the risk of the exposure to radiation, it is not easily recommended to patients 
from time to time. MRI may pose difficulty in the clear observation of the colon structure, 
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as the colon moves during peristaltic exercise and the measurements may take a long time. 
Although PET is a powerful technology to detect metastasized cancer, very few hospitals 
have this facility. These techniques (X-CT, MRI, PET, and endoscopy) rely on the 
morphological observations such as the shape and size of the suspicious lesion, and 
clinicians often require additional direct observation of the tissue to make confirmatory 
diagnosis. Histopathology with tissue biopsy is a gold standard for the definite diagnosis 
of cancer. However, it is highly invasive and requires a long time for sample preparation 
before microscopic observation. The number of pathologists in 2017 is 2,405, and the 
number of hospitals is 8,439. It is concerned that the load of pathologists increases rapidly 
as the number of biopsy required increases. Hence, reliable diagnostic techniques that 
reduce invasiveness and provide objective data are desirable to improve the accuracy of 
endoscopy-based cancer diagnosis.  
In recent years, Raman spectroscopy has attracted the attention of researchers as 
a technique for cancer diagnosis. It is one of the measurement techniques that provide 
subjective data of biological samples with low invasiveness. In 1928, C. V. Raman 
discovered scattered light exhibiting different frequencies upon irradiation of carbon 
tetrachloride (CCl4) with monochromatic light, for which he was awarded the Nobel Prize 
in 1930. This phenomenon, termed as the Raman effect, after his name11,12, is attributed 
to energy transition in a molecule between the ground state and the excited vibrational 
state. As the vibrational level is unique to the molecule, vibrational spectroscopy is able 
to determine and identify molecules present in any sample. The applications of Raman 
spectroscopy were limited until the development of the first laser in 1960. Many 
researchers have used Raman spectroscopy to study biological samples, owing to its low 
invasiveness13. Ozaki et al. obtained the Raman spectra of proteins from the eye lens using 
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argon ion visible excitation laser (488 nm)14. However, almost all biomaterials emit strong 
fluorescence and are weak substrates for laser illumination15. Fluorescence may pose a 
problem while using Raman spectroscopy for biological samples. In 1980s, Fourier 
transform (FT) Raman spectroscopy that employs an oscillation line of Nd-YaG laser at 
1064 nm for light excitation was developed to eliminate fluorescence noise15,16. Raman 
spectra of many biological samples were successfully obtained using FT Raman 
spectroscopy. However, the detection sensitivity was low and the time to measure FT 
Raman spectrum was considerable. In the 1990s, a different type of near-infrared (NIR) 
excitation Raman spectrometer equipped with a sensitive and commercial charge-coupled 
device (CCD) detector, a high throughput dispersion spectrometer, and an NIR diode laser 
that emitted light from 700 to 860 nm wavelength became popular. This instrument 
allowed the measurement of Raman spectrum in a shorter time than that with the FT 
Raman instrument. Coupling it with an optical fiber was easy, as NIR light exhibits high 
throughput in normal glass fiber for biomedical Raman spectroscopy17,18. 
In comparison with other vibrational spectroscopy techniques, NIR excitation 
Raman spectroscopy offers some advantages. Fourier transformed infrared (FT-IR) 
absorbance spectroscopy, a technique related to Raman spectroscopy, is one of the 
vibrational spectroscopy methods19 used for the analysis of organic materials. However, 
FT-IR spectroscopy may not be useful for biomedical study. As water has high absorption 
in infrared and NIR regions, it is difficult to measure water-based samples such as 
biological samples with FT-IR spectroscopy. Materials with covalent bonds exhibit 
vibrational energy. IR light has very low penetration efficiency for most of the optical 
materials. Currently, very few materials are available for optical fiber IR light. In contrast, 
visible and NIR light (~1200 nm) are used for the measurement of Raman spectrum. Glass 
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and water have no absorption in these regions. Moreover, the Raman band of water does 
not overlap with the finger print region (~1800 cm−1) of usual organic materials. All these 
features deem Raman spectroscopy suitable for bioanalysis. 
Raman spectra of biological materials comprise complex bands, owing to the 
overlapping peaks arising from various chemical materials20. Chemometrics, a 
mathematical technique based on statics, is applied to analyze complex data and extract 
useful information from a series of datasets for easy understanding. Chemometrics allows 
visualization and easy understanding of the change in the data group without arbitrariness, 
thereby serving as an important tool for the analysis of Raman spectra of biological 
samples. 
Many researchers have reported in situ analysis of cancers by Raman 
spectroscopy and fiber optic Raman probes. Raman spectroscopy was applied for the first 
time to explore the implications of early detection of neoplastic lesions in the human 
stomach during clinical gastroscopic observation. Bergholt et al. developed a 1.8-mm 
diameter Raman probe for its use in the human stomach21 and suggested that cancerous 
tissues could be identified in the stomach and esophagus at an accuracy of 89.3% and 
94.7%, respectively, using Raman spectroscopy and partial least squares-discriminant 
analysis (PLS-DA) as one of the chemometrics22. Furthermore, Haka et al. suggested the 
application of Raman endoscopy for human breast cancer diagnosis (ex vivo study)23.  
The purpose of this study was to develop Raman spectroscopic techniques for 
supporting in situ cancer diagnosis with endoscopic observation. This study may provide 
objective data to clinicians to improve the accuracy of endoscopic diagnosis. In this 
direction, fundamental research on colorectal cancer tissues using Raman spectroscopy is 
desirable. Many researchers have developed techniques to discriminate between benign 
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and malignant tumor. Clinicians may not rely on Raman spectroscopy data for making 
confirmatory diagnosis, as Raman spectroscopy shows no morphological information but 
may provide detailed information of molecular composition changes. Therefore, it is 
necessary to accumulate sufficient amount of basic data and research results to prove 
reliable diagnosis with Raman spectroscopy in the absence of morphological information. 
To the best of my knowledge, no technique allows the direct observation of the 
advancement in cancer. M. V. Schulmerich et al. reported in vivo measurement of murine 
bones under anesthesia using Raman spectroscopy24. The present study was encouraged 
based on the results of previous studies for monitoring the tumor (colorectal tumor) in a 
single living mouse model to provide sufficient reliable data. 
The use of a mouse model offers several advantages. It is possible to monitor the 
advancement of tumor from early stages and during the chemotherapy treatment process 
using a mouse model. Moreover, the individual discordance is eliminated, as the mice are 
isogenic. The azoxymethane–dextran sodium sulfate (AOM–DSS) colon cancer mouse 
model was used in the present study, as the tumor advances very rapidly in this model, 
and a month is enough for the sample preparation25. The tumor often advances into 
adenocarcinoma in this model26, which was used herein to monitor the advancement of 
tumors, using Raman spectroscopy. The problem in using a mouse model was its small 
size. The normal endoscope with the Raman probe used for human studies was too large 
for the mouse model. Hattori et al. and Komachi et al. developed a miniaturized Raman 
endoscopic (mRE) system for mouse studies27-29. The diameter of the endoscope head 
was 2.5 mm and included a channel with a 1.2-mm diameter. A ball lens-installed hollow 
optical fiber Raman probe (BHRP) with a 0.64-mm diameter was attached on to the probe 
head30–32. This system was small enough to measure the mouse colon tumor under 
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anesthesia treatment, while BHRP allowed noninvasive measurement of tissues. The first 
study involved the use of established techniques for in situ noninvasive observation of 
the same tumor to monitor the advancement of cancer in a live mouse model using an 
mRE system with BHRP and development of procedures for the efficient analysis of the 
Raman spectra with chemometrics. In the next step, the efficiency of this instrument was 
evaluated. In the second study, the effects of anticancer drugs were studied using an mRE 
system in the mouse model. Anticancer drug treatment is one of the standard treatments 
for colorectal cancer. Monitoring the effect of anticancer drugs by Raman spectroscopy 
has been conducted in cultured cells33. Skolekova et al. reported the effects of anticancer 
agents on cancer cells34. Ock et al. reported real-time monitoring of anticancer drug 
effects on cancer cells using surface-enhanced Raman spectroscopy35. These studies 
strongly suggest that Raman spectroscopy may be useful for monitoring the effects of 
anticancer drugs at the cellular level. The molecular biological study of cultured cancer 
cells may provide information on the anticancer effects of drugs. However, this 
information may be insufficient to understand cancer tissue, owing to the complexity of 
cancer tissues as compared with cells36. The mRE system and mouse model allowed direct 
monitoring of tumors. 
Under clinical settings, cancer diagnosis is based on imaging techniques such as 
histopathology and endoscopic diagnosis. The Raman image system comprises a 
microscope Raman spectrometer and confocal imaging system on a computed micro-
stage. The sample for observation may be inserted into the sampling stage of the 
microscope. It is necessary to process the sample and it may be difficult to evaluate live 
tissues. Autofluorescence imaging has been used to study colorectal cancer. Aubin et al. 
suggested that nicotinamide adenine dinucleotide (NADH) and flavin exhibit 
- 7 - 
 
autofluorescence in viable cells37. Barenbiom et al. reported that elastin and collagen 
present extensively in the extracellular matrix and emit autofluorescence38. The 
measurement of NADH in viable cells and extracellular matrix may provide structural 
information of the tumor tissue, as tumor tissue contains complex structures such as 
cancer stem cells and extracellular matrix. The site dependency of viable cells and 
extracellular matrix was studied in live tumors by comparing the autofluorescence image 
with Raman spectra to study the complex structure of tumor tissues in third chapter.  
The first and second chapters have already been published in journals39,40. 
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Ⅰ - 1. Abstract 
The aim of the present study is to evaluate the capability of a miniaturized Raman 
endoscope (mRE) system to monitor the advancement of colorectal tumors in model mice 
as a method that is noninvasive to the tumor itself. Nevertheless, the endoscope is narrow 
enough to observe the inside of the mouse colon in such a way that is semi-noninvasive 
to the animal. However, the mRE system allowed the visualization and Raman spectral 
measurement of any targeted point within the colorectal tumor in model mice under 
anesthesia, without damaging the tissue (i.e., noninvasively). Continuous monitoring of 
the same tumor allowed the observation of alterations in its molecular composition and 
size, along with its advancement. The tumor lesion was discriminated from normal tissues 
of the control mouse with an accuracy of 86.8%. I succeeded in visualizing and 
performing Raman spectral observations on a shrinking polyp type tumor. The Raman 
analysis suggested that it was not cured but supposedly transformed to another tumor type. 
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Ⅰ - 2. Introduction 
Colorectal cancer is the third most cancer death in men and first most cancer 
death in women in Japan1. Colorectal cancer is generated by mutations in tumor-
suppressor genes and oncogenes activated in the colon epithelium. After further mutations 
in tumor-suppressor genes such as p53, matrix metalloproteinase is expressed in the tumor 
cells, leading to the destruction of the basal lamina consisting of collagen IV, and then the 
tumor acquires the ability to metastasize2,3. Early stage tumors in the colorectal 
epithelium are generally benign and usually in the form of an adenoma. However, these 
tumors can metastasize, and therefore, be classified as adenocarcinoma. Determining 
whether a tumor is malignant or benign is difficult based on its visual appearance4,5. 
Raman spectroscopy had been applied to explore the implications of early 
detection of neoplastic lesions in the human stomach during clinical gastroscopy, and 
excitation laser was introduced a 1.8 mm Raman endoscopic probe for the in situ 
measurement6. Bergholt et al., reported that cancerous tissues could be identified inside 
the stomach and esophagus with an accuracy of 89.3% and 94.7%, respectively6,7. 
Meanwhile, Raman endoscopy can be suggested for human breast cancer diagnosis (ex 
vivo study)8. Their results showed a sensitivity of 83% and a specificity of 93% for the 
evaluation of freshly excised surgical specimens8. In the case of colorectal cancer 
diagnosis, Zheng et al. reported about the Raman analysis of single live epithelial cells, 
in which the method showed about 86.3% sensitivity and 86.3% specificity9. 
The purpose of the present study is to demonstrate that the molecular changes of 
a tumor lesion can be studied over a long period in a live mouse by using the miniaturized 
Raman endoscope (mRE) system. The use of a mouse model makes it possible to monitor 
the advancement of the tumor from the very early stage through the treatment process 
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during chemotherapy. Moreover, it can eliminate individual discordance. In generating 
the tumor model, the same tumor type is usually produced because the mouse is isogenic; 
moreover, the initiator and the promoter of carcinogenesis are identical to all the mice. It 
is impossible to do a similar observation in human subjects. Nevertheless, the problem in 
using a mouse model is its size. The normal endoscope with a Raman probe used for 
human studies is too large for the mouse model. Hence, we developed the present mRE 
system for mouse studies10-12. The diameter of the endoscope head is 2.5 mm, including 
a channel with 1.2 mm diameter. A ball lens-installed hollow optical fiber Raman probe 
(BHRP) with 0.64 mm diameter is inserted into the channel13–15. Raman spectroscopy 
allows us to obtain information about molecular concentrations and the structural 
composition of tumor tissues in situ in a totally noninvasive manner. The long-term aim 
of this study is to develop a technique for analyzing the characteristic molecular 
compositions of adenomas and adenocarcinomas, and for monitoring the effect of 
anticancer drugs in situ. To reach this aim, the present study focuses on collecting 
preliminary knowledge and examining the performance of the system. We have developed 
a method for monitoring the molecular changes in an axillary tumor in a living rat by 
injecting BHRP into the tumor via an injection needle15. The early detection of the cancer 
is not the major purpose at this time.  
The azoxymethane–dextran sodium sulfate (AOM–DSS) colon cancer model 
mice were used in the present study because the tumor advances very rapidly in this model 
and only 1 month is needed for sample preparation16. AOM-DSS model has been found 
to be more potent and stable in solution than 1,2-dimethylhydrazine models17. Moreover, 
the tumor often advances into adenocarcinoma in this model18. However, no concrete 
knowledge is available about the advancement of these tumors. Therefore, monitoring the 
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same tumor (colorectal tumor) in a single mouse is necessary for a reliable analysis. In 
the present study, performing Raman measurement under the guide of visual observation 
in individual live mice and analyzing the molecular alterations dependent on the 
advancement of the tumor were successfully carried out. 
 
Ⅰ - 3. Material and Methods 
1. Preparation of AOM–DSS colorectal cancer model mice  
BALB/cCrSlc mice were purchased from SLC (Shizuoka, Japan). The 
azoxymethane (AOM) and dextran sodium sulfate (DSS) were purchased from Sigma-
Aldrich Chemical Co. (St. Louis, MO, USA). The saline (Otsuka Pharmaceutical Co., 
Ltd., Tokushima, Japan) solution of AOM was administrated by intraperitoneal injection 
(7.4 mg kg-1) once to each 8 week old mouse17. The mice were then given DSS in drinking 
water (30 mg ml-1). DSS administration had a duration of 1 week and was repeated twice 
with a 2 week interval16. A tumor was observed in all mice (16 heads) at 15 weeks after 
AOM administration. Four of 16 heads mice, which have developed tumor lesions, 
possessed good recognizable tumor performance for Raman measurement and were used 
for further studies. Several control mice were kept under the same conditions as the model 
mice. Measurements of 3 model mice (A–C) and 1 control mouse (N) were carried out at 
15, 17, and 19 weeks of age, and the remaining model mouse (D) was assessed at 16 and 
18 weeks. Carcinogenesis of these colorectal tumors was confirmed by histopathological 
study in Biopathology Institute Co., Ltd(Oita, Japan). 
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2. Raman measurements 
The Raman system was equipped with a miniaturized endoscope and a ball lens-
installed hollow optical fiber Raman probe (BHRP)13-15. The endoscope was made by 
Machida Endoscope Co. Ltd. (Japan). The homemade BHRP consisted of a sapphire ball 
lens of 500 mm diameter (Edmund Optics, USA) and a hollow optical fiber of 420 mm 
outer diameter (Doko Engineering LLC, Japan)9-12. Combining miniturized endoscope 
and BHRP made mRE system. A diode laser emitting at 785 nm (Toptica Photonics, 
Germany) was used for excitation during the Raman measurements. A single 
polychromatic Raman spectrometer (F4.2, focal length 320 mm, 750 nm blazed 600 l 
mm-1 grating; Photon Design Co. Ltd., Japan) and a charge coupled device detector 
(DU420-BRDD; Andor Technology Co. Ltd., Northern Ireland) were used to record the 
Raman spectra. The BHRP was coupled to the spectrometer through a long-pass filter 
(LF; Semrock, USA), a notch filter (NF; Kaiser Optical System, USA), and 2 lenses to 
focus the laser and Raman scattered light into the hollow optical fiber and the slit (100 
mm width). Fig. 1-1 describes this mini-endoscope and Raman system. Spectra for a 60 
second exposure of the sample to a 60 mW excitation light were acquired.  
 
Fig.1-1 The structure of the miniaturized Raman endoscopic system with schematic drawing of the 
experimental setup.  
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3. Procedure for endoscopic observation 
Mice were anesthetized with an inhalation anesthesia apparatus (SurgiVet, USA) 
and kept on a warming plate to maintain the body temperature at about 37 ℃. The mice 
were then positioned on a specialized circuit board that can control heating19. The 
concentration of isoflurane (Mylan, Tokyo, Japan) was 1.0–2.5%. Isoflurane has a lower 
concentration than that is recommended by Piramal Healthcare Ltd., London, UK with 
the volume-to-volume (v/v) of 3–5%19. The endoscope was inserted from the anus, and 
then the lumen was pressurized with air via the channel to keep the field of view. Feces 
that remained in the colon were removed by washing off the colon with saline. The BHRP 
was inserted into the endoscope's channel to measure the Raman spectra (Fig. 1-1). The 
distance of the tumor from the anus was recorded through repeated measurements. The 
method worked well, and no other markers were necessary for recognizing the same 
tumor in each mouse during this experiment. This study was approved by the ethics 
committee of Kwansei Gakuin University. 
 
4. Histology study 
Particularly in histology studies, whole specimens are immediately fixed with 
4% paraformaldehyde at 4 ℃, dehydrated through a graded series of ethanol (70%, 80%, 
90%, 95%, and 100%), continued immersing in histo-clear, and embedded in paraffin20. 
The sections were 5 µm thick and stained with hematoxylin–eosin (H/E). The degree of 
morphological alteration in the tissue sections was graded by experienced pathologists 
who were blind to spectroscopic data. 
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5. Data analysis 
First, a background spectrum due to the Raman probe was subtracted from the 
recorded spectra, and the measured spectra were later background-corrected. The 5th 
polynomial line fit to the spectrum was subtracted from the spectra. Spectral areas having 
a negative value were extracted. The extracted areas were subjected to a 5th polynomial 
fitting and another subtraction. The same procedure was repeated 5 times to obtain the 
background-corrected spectra. Then, the spectral intensities were standardized with a 
phenylalanine band at 1003 cm-1, which was adequately sharp to determine its accurate 
intensity. These collection procedures are necessary for the further analysis8. A 
chemometrics software program (Unscrambler; CAMO, USA) was used for principal 
component analysis (PCA), partial least square regression (PLSR) analysis, and linear 
discriminant analysis (LDA)21,22. PCA is able to obtain the maximum variance from 
complex data as the principal component (PC) and find the correlation of these data. 
PLSR, similar method to PCA, find the linear differences from complex data as the factor. 
LDA is a classification method of searching for a linear combination of the variables that 
best separates two classes. The minimum level of smoothing (11 points) was carried out 
with the Savitzky–Golay method to show the bands clearer to the spectra shown in Fig. 
1-2. However, the spectra without smoothing were used for the further spectral analysis 
to minimize the artificial effect. 
 
Ⅰ - 4. Results 
1. Raman measurements of colorectal tumors in model mice 
Mice that have too large tumors in the rectum were excluded from the study due 
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to the difficulty of deeply inserting the endoscope without scratching the vulnerable tumor 
 
Fig.1-2 Raman spectra of tumors (averaged) measured in 3 tumor models, at 15 (a and d), 17 (b and 
e), and 19 (c and f) weeks of age (tumor model: 15 weeks, n = 19; 17 weeks, n = 24; 19 weeks, n = 
19; control: 15 weeks, n = 7; 17 weeks, n = 9; 19 weeks, n = 7) 
 
Fig.1-3 (A) photograph of a typical colon tumor measured with the endoscope in a 15 week old live 
model mouse, the tumor is marked with a broken line (---), the distance of the tumor from the anus is 
±14 mm, the head of the BHRP (*) and the lumen of colon (**) are seen in the picture; (B) 
photomicrograph of a hematoxylin–eosin-stained colorectal adenocarcinoma in Fig. 1-3 A(---), the 
tissue was collected from a killed mouse (19 weeks old) and necrotic tumor cells (a), cancer cells (b), 
and normal cells (c) can be seen. 
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lesion. I selected 4 of 16 mice that have the best tumor configuration (i.e., the tumor has 
an easy-to-access location and is easily recognizable for continued endoscopic 
observation) for further observation. The head part of the endoscope could be bent up and 
down with a lever at its handle. The handle is rotated to turn the sight into either the right 
or the left direction. To point the probe toward a closer or farther tissue, the probe rod is 
pulled or pushed. With these simple manipulations, it is possible to reach any point within 
the colon through the visual guide of a TV monitor. A typical endoscope picture of a colon 
tumor in the mouse model is shown in Fig. 1-3A. The distal end of the BHRP can be seen 
at the right side of the sight. Generally, several (3–7) polyp-shaped tumors were observed 
in each mouse. A photomicrograph of an H/E-stained adenocarcinoma tissue is shown in 
Fig. 1-3B, which indicates that the tumor in the AOM/DDS mouse model has advanced 
into the malignant state. The tissue sample was obtained from a large polyp-like dysplasia. 
On the basis of our histopathologic examinations, an estimated 5–10% of tumors in the 
20 week old mice are adenocarcinoma and the other tumors are adenoma.  
 
2. Analysis of Raman spectra from colorectal tumors in model mice 
 The Raman spectra of live tumor model and control mice are shown in Fig. 1-2. 
I selected several polyp-like tumors in the 3 model mice and the measurements were 
repeatedly carried out at 15, 17, and 19 weeks of age (7th, 9th and 11th weeks after the 
administration of AOM). Several spectra were collected from different polyps in each 
model mouse and they were collected from different positions in the colon wall for the 
control mouse. The total numbers of the measured spectra were 19, 24 and 19 for 15 (a), 
17 (b) and 19 (c) weeks of tumor models and 7, 9 and 7 for 15 (d), 17 (e) and 19 (f) weeks 
of control. The Raman spectra were analyzed with PLSR analysis The PLSR score plot 
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and loading plot for factors 1 and 2 calculated for 3 tumor mice are shown in Fig. 1-4A 
and C. The dataset is classified into 3 groups according to the number of weeks. The 
bands at 1662, 1451, and 1342 cm-1 are assigned to amide I, C-H bending, and amide III 
vibrational modes of protein in factor 1, and the bands at 1736, 1655, and 1441 cm-1 were 
assigned to C=O stretching, C=C stretching and C–H bending modes of triacylglycerol 
in factor 2, respectively. This tendency is observed more clearly in the PLSR score plot 
calculated for a single mouse. The score and loading plots of the spectra obtained from 
one mouse alone are shown in Fig. 1-4B and D. These score plots indicate that molecular 
alterations occurred as the tumor advanced. The results suggest that the tumor developed 
in one direction and all tumors showed a relatively uniform 
 
Fig.1-4 Score and loading plots for factors 1 and 2 of PLSR models obtained for the spectra measured 
in 3 tumor mouse models (A and C) and in a single tumor mouse model (B and D). Marks of ●, □ 
and ▲ represent the spectral data measuread at 15, 17, 19 weeks of age, respectively. The Raman 
spectra weremeasured at several tumor lesions in the mouse; for the 3 tumor mouse models, the total 
number of spectra are 19, 24 and 19 for 15, 17 and 19 weeks, for the single tumor mouse model, the 
total number of spectra are 8, 7 and 7 for 15, 17 and 19 weeks. 
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phase of development in the AOM/DSS mouse model. The validation result of the spectra 
of the control mouse applied to the PLSR model obtained for the 3 tumor mice is depicted 
in Fig. 1-5. When the control data applied to the PLSR model obtained for the tumor 
advancing, the prediction result has no relationship with the weeks of mouse. If the PLSR 
model reflected the usual aging effect of the colorectal tissue, the data would be classified 
depending on the weeks. It is not the case. The result strongly suggests that the PLSR 
model of the tumor mice successfully extracted specific information to the tumor 
progression. Fig. 1-6 shows a PCA score plot (A) and loading plots (B; principal 
components (PCs) 1 (a) and 2 (b) ) calculated for the spectra of the tumor lesion in 2 
model mice (B and C; n = 41) and for the control mouse (N; n = 23). The spectra of these 
3 mice, including data obtained at different ages (15–19 weeks), were analyzed together. 
 
Fig.1-6 Score plot (A) for PC1 and 2 of a PCA 
model built for the Raman spectra obtained from 
control (● ; n = 22) and tumor (□ ; n = 41) mice, 
and loading plots (B) of PC1 (a) and 2 (b) 
 
Fig. 1-5 Prediction result of the dataset of the 
control mouse (15 weeks n = 7, 17 weeks n=9, 
19 weeks n = 7) applied to the PLSR model. 
Bars (-) represent prediction values and vertical 
bars do represent deviations of the prediction 
values. 
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Strong five bands appeared at 1654, 
1440, 1304, 1263, and 933 cm-1 in the 
loading plot of PC1 in Fig. 1-6B (a), 
which seemed to be assignable to 
lipids. I have inspected score plots for 
PC1 to PC7; however, no clear 
classification, including the week 
dependency, was observed. It seems 
that PLSR can extract information more efficiently depending on the dependent variables. 
Judging from the features of the loadings, PC1 and 2 are mostly arising from the protein 
in the negative direction and fat (triacylglycerol) in the positive direction. This judging 
due to the bands at 1662, 1451, and 1342 cm-1 is assigned to amide I, C-H bending23, and 
amide III vibrational modes of protein24 in PC1. Meanwhile, the bands at 1736, 1655, and 
1441 cm-1 were assigned to C=O stretching25, C=C stretching26, and C–H bending modes 
of triacylglycerol27 in PC2. The PCA score plot (A) and loading plots (B; PC1 and 2) in 
Fig. 1-6 were calculated for the spectra of model and control mice. Although the control 
and tumor spectra were not discriminated in the score plot, the spectra of the control 
mouse showed a tendency to have a larger PC1 contribution. Five bands strongly 
appeared at 1654, 1440, 1304, 1263, and 933 cm-1 in the loading plot of PC1, which 
seemed to be assignable to lipids. The result suggests that the normal colon tissue has a 
higher lipid concentration than the tumor. The data of the normal mouse and those of the 
tumor model mice were then analyzed with LDA. The LDA score plot is depicted in Fig. 
1-7. The LDA model was constructed for the spectra of control (N; n = 23) and tumor 
mice (B and C; n = 41). The spectra of different tumor model mice (A and D; n = 38) 
 
Fig.1-7 LDA score plot of the control dataset (○), tumor 
dataset (×), and validation dataset (△). 
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were used to validate the model. LDA was applied to the sample data with these 5 bands. 
The result showed that 86.8% (n = 33) of tumor samples were classified correctly and 
13.2% (n = 5) incorrectly. Since all of the control data were used to obtain a reliable model, 
there is no control spectra left for validation. The validation is made with the spectra of 
different tumor model mice which were not used to build the model. Therefore, the 
present LDA model is relatively robust. Fig. 1-8A depicts a series of pictures of a 
shrinking tumor in the same mouse. These are endoscopic pictures observed at the same 
position in a model mouse at 15, 17, and 19 weeks of age. A small tumor is visible in the 
first picture (Fig. 1-8A(a)), slightly larger tumor appeared in the second picture (Fig. 1-
8A(b)), and then in the third picture (Fig. 1-8A(c)) these tumors disappeared. The 
observed point was at 14 mm from the anus. Although a few tumors showed a reduction 
in size (shrinking tumors) during the observation, I have succeeded in simultaneously 
recording both pictures and spectral data in only one case because this was not a 
predictable phenomenon. In this case, the tumor seemed to have disappeared; however, 
the other tumors were only reduced in size. The shrinking tumors were generally small; 
however, no characteristic feature was recognized from the visual observation. The 
Raman spectra of this lesion are shown in Fig. 1-8B. The spectra of the shrinking tumor 
measured at 15 (Fig. 1-8B(a)), 17 (Fig. 1-8B(b)), and 19 (Fig. 1-8B(c)) weeks are depicted. 
The spectra in Fig. 1-8B(d) and (e) are the subtraction results of the 17 week spectrum 
minus the 15 week spectrum and the 19 week spectrum minus the 15 week spectrum, 
respectively. The spectra of the shrinking tumor measured at 15 (Fig. 1-8B(a)), 17 (Fig. 
1-8B(b)), and 19 (Fig. 1-8B(c)) weeks showed similar features to those of the growing 
tumors shown in Fig. 1-3. The subtraction spectrum in Fig. 1-8B(d) shows a negative 
band at 933 cm-1, which may be arising from collagen type I28 and may indicate the less-
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activity of tissue repair. Since the spectra were too noisy to collect information with visual 
comparison, the previous LDA model was applied for 
 
Fig.1-8 The pictures of shrinking tumor (A; 14 mm from anus) taken at mouse ages of 15 (a), 17(b) 
and 19(c) weeks; the Raman spectra of tumors (B; averaged) measured at mouse ages of 15 (a), 17 (b), 
and 19 (c) weeks, and the subtractions spectra of 17 weeks minus 15 weeks (d) and 19weeks minus 15 
weeks (e). The spectra in the 1545-1559 cm-1 range were hidden to remove a strong noise due to the 
oxygen in the hollow fiber. The tumor is shown with dotted line (---). The head of the BHRP was 
marked by ''*''. The lesion with a ''**'' mark indicates the lumen of the colon. 
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diagnosis. Fig. 1-9 is the LDA score plot 
of the 15 weeks dataset (×), 17 weeks 
dataset (*), and 19 weeks dataset (●) 
used by LDA model in Fig.1-7. The 
spectra of the shrinking tumor were 
classified as “tumor” in Fig.1-9. It 
suggested that the shrunken tumor was 
disappeared by observation but Raman 
spectroscopy found the tumor. However, 
the shrunken tumor were not checked up and diagnosed by histopathologists due to unable 
to recognize the exact position of  the shrunken tumor after sacrificed. 
 
Ⅰ - 5. Discussion 
Observation and measurement of Raman spectra in individual mice were carried 
out repetitively during a 2 weeks interval to prevent the adverse effects of anesthesia. 
After the observation at 19 weeks, the mice were sacrificed for histopathological studies. 
Cautious observation of the extracted colon as well as endoscopic observation indicated 
that the Raman measurements with 60 mW laser irradiation did not cause any damage to 
the tissue. Not only the low level of laser irradiation, but the exposure time of laser was 
short enough, which did not cause the accumulation of energy to be hot and consequently 
give effect to the tissue. The laser irradiation level and exposure time will have a 
relationship with the damage of tissue23. Furthermore, pathologic analysis of the 
biological effects of laser–tissue interaction needs a relationship of the irradiation 
parameters with the biologic status and response of the target tissue over time29. 
 
Fig.1-9 LDA score plot of the 15 weeks dataset (×), 
17 weeks dataset (*), and 19 weeks dataset (●) of 
shrinking tumor. 
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Visual observation indicated that the tumors mostly grew in size during the 4 
weeks but no other obvious changes were observed. Bands at 1654, 1440, 1263, and 1003 
cm-1 were assigned to the amide I, C–H bending, and amide III vibrational modes of 
protein, and a breathing mode of the phenyl ring of phenylalanine30, respectively. It 
seemed that a band at 933 cm-1 can be assigned to proline in collagen type I31,32. As the 
bands at 1654, 1440, and 1304 cm-1 seemed to have trace contributions of a lipid24,33. The 
working distance and the size of the focal volume were 60 and 58 µm the depth direction, 
respectively9. The tumor part is usually much thicker due to the dysplasia as shown in Fig. 
1-1C. The lipid seems to be included in the tumor tissue itself.  
The present study demonstrates that an in vivo study with a miniaturized Raman 
probe and a miniaturized endoscope is a powerful method for obtaining molecular and 
morphological information of tissues in real time without damaging the tissue. Although 
no bleeding occurred during the operation, the anesthesia procedure is still necessary for 
studies with this colorectal tumor mouse model. From this viewpoint, although 
introducing the endoscope may be a semi-noninvasive method, the procedure might still 
cause pain to the animals. The possibility of monitoring unique alterations in the 
molecular composition of the colorectal tumor will allow us to study the therapeutic 
effects of not only anticancer drugs but also various medical treatments, using individual 
model mice. The technique may also contribute to reducing the number of mice to be 
killed in studies. The tumor grade was not discussed in this study because I focused on 
the noninvasive observation of the tumors. It was possible to conduct a biopsy for a part 
of the tissue with forceps; however, it might cause severe inflammation, infection, and 
irregular tissue formation during repair. The present results reveal that the molecular 
composition of a tumor changes as the tumor advances.  
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This kind of study would be very difficult to use other tumor animal models such 
as the dog or sheep model because it would take a long time to create the model and to 
advance the tumor in these medium-sized animals. Although the mouse model is too small 
for the commercially available endoscopes, it has the advantage of ease in preparation 
and tumor control. The present system allows the use of a mouse model to study the 
molecular alterations and the morphology of live tumor tissues continuously.  
 
Ⅰ - 6. Conclusion 
The present study demonstrated that this Raman system equipped with a 
miniaturized endoscope and BHRP can simultaneously obtain spectral and visual 
information on the same tumor in a single mouse through continued measurements for 
several weeks. The results of Raman monitoring of tumors suggested some biochemical 
alterations in the molecular composition of the tumor, such as the change in the 
concentration of collagen type I and lipids in the lesion. The LDA model was constructed 
with 5 bands mainly assigned to lipids distinguishing the tumor and the control tissues. I 
have succeeded in observing and measuring the Raman spectra of a shrinking tumor. 
According to the LDA analysis, the shrinking tumor was not cured but rather transformed 
to another tumor type. The animal test using a mouse is irreplaceable for the basic research 
of tumor. The present technique can contribute to open a new era into the advanced mouse 
model research.  
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ⅠⅠ - 1. Abstract 
I have developed a murine model to study the effects of anticancer treatment on 
colorectal tumors. A miniaturized Raman endoscope (mRE) system was employed for the 
study. The endoscope is narrow enough to observe the inside of the mouse colon under 
anesthesia. It has a channel for a ball lens mounted on a hollow fiber Raman probe 
(BHRP) to measure any targeted point under the visual control of the endoscope. 
Colorectal cancer tissue was observed to study alterations of the tissue in response to 
anticancer drug treatment. Three anticancer drugs, 5-fluorouracil (5-FU), cisplatin 
(CDDP), and docetaxel were employed. Although no alteration was recognized in the 
endoscopic visual observations at 2 weeks after the drug treatments, the Raman spectra 
obtained in the live mouse colon indicated that changes of lipids and proteins were 
observed. This study demonstrates that in situ Raman analysis is powerful in detecting 
the effects of anticancer drugs. 
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ⅠⅠ - 2. Introduction 
Colorectal cancer is the third most cancer death in men and first most cancer death 
in women in Japan1 and anticancer drugs are a mainstay in treating any cancer. There are 
many kinds of anticancer drugs but they can cause severe side effects. Therefore, it is 
necessary to select the most effective drugs for each case while limiting side effects. This 
is not straightforward because of the individual characteristics of each cancer. During 
chemotherapy, higher doses are preferable to destroy cancer cells but the dosage may 
need to be limited in order to minimize side effects2. In clinic, selection of cancer drugs 
is based on doctor’s experience and knowledge3. The selected drugs have to work greater 
efficiency and lower toxicity for patients4.  
The purpose of the present study was to develop a technology to estimate the 
efficiency of anticancer drugs over short periods of time. For this purpose, I applied 
Raman spectroscopy via endoscope to evaluate the effects of different anticancer drugs 
in a noninvasive manner. It is difficult to do this with repeated biopsies because of their 
invasive character. For continuous measurement of responses, minimally invasive 
methodologies are required. Raman spectroscopy provides information about the 
molecular composition without damaging the tissue (i.e., noninvasively)5. I used the 
azoxymethane-dextran sodium sulfate (AOM-DSS) colon cancer mouse model because 
the tumor progresses very rapidly and only 1 month is needed for sample preparation. 
Such a model is easily manipulated, allowing a well-controlled environment for cancer 
research6. 
Raman spectroscopy has been applied to explore the implications of early cancer 
detection in the human stomach during clinical gastroscopy, which led to the development 
of a 1.8 mm Raman endoscopic probe for in situ measurements. Cancerous tissues can be 
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identified inside the stomach and esophagus with an accuracy of 89.3% and 94.7%, 
respectively7. Meanwhile, Raman endoscopy has been suggested for human breast cancer 
diagnosis (in an ex vivo study)5. This study reported a sensitivity of 83% and a specificity 
of 93% for the evaluation of freshly excised surgical specimens. For colorectal cancer 
diagnosis, it has been reported that the Raman analysis of single live epithelial cell had a 
sensitivity of 86.3% and a specificity of 86.3%8. 
This present study was to evaluate the effect of anticancer drugs in live colorectal 
cancer mouse models using a Raman endoscope system. We have developed a 
miniaturized Raman probe and an endoscope specifically for use in the mouse7,9,10. A ball 
lens-installed hollow optical fiber Raman probe (BHRP) consists of a sapphire ball lens 
and a hollow optical fiber11,12. The endoscope system allows the direct observation of the 
tumor in the colon. The colorectal cancer model is created through the administration of 
azoxymethane (AOM) and dextran sodium sulfate (DSS)6. Live tumor-bearing mice are 
then treated with one of three anticancer drugs, 5-fluorouracil (5-FU), cisplatin (CDDP), 
or docetaxel.  
5-FU is an analog of uracil with a fluorine atom at the C-5 position instead of 
hydrogen. 5-FU is converted intracellularly to several active metabolites, including 
fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP), 
and fluorouridine triphosphate (FUTP); these active metabolites disrupt DNA and RNA 
synthesis and the action of thymidylate synthase (TS)13. CDDP interacts with DNA to 
form DNA adducts, primarily intra-strand crosslink adducts, which activate several signal 
transduction pathways, including those involving ATR, p53, p73, and MAPK, and 
culminates in the activation of apoptosis14. Docetaxel is a semisynthetic taxane. Docetaxel 
targets the β subunit of tubulin heterodimers, thereby stabilizing microtubules and 
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inducing cell-cycle arrest and apoptosis15. These drugs all disrupt cellular activity to 
interfere with the cell cycle and/or mitosis and induce cell death but their mechanisms are 
different.  
Principal component analysis (PCA) was employed for the classification of the 
Raman spectra related to the anticancer drug treatment and control groups to detect tissue 
alterations in response to drug treatment. I hypothesized that Raman analysis would be 
able to discriminate the effects of these drugs based on the molecular compositional 
changes they induced.  
Reactions of cancer cells to anticancer drugs have been studied in vitro using 
Raman imaging16. Cancer tissue consists of not only cancer cells but also extracellular 
matrix, and many other cells, e.g., macrophages and vascular endothelial cells. Among 
the various types of cells, cancer stem cells have tumorigenic capacity and their presence 
seems to closely correlate with tumor drug resistance17. Skolekova et al. reported that 
pretreatment of human mesenchymal cells with CDDP led to changes in the 
phosphorylation profiles of many kinases and also increased secretion of IL-6 and IL-8 
cytokines, which increased the chemoresistance and stem cell characteristics of breast 
cancer cells18. In addition, high collagen content in a tumor's extracellular matrix and its 
organization into a thick fibrous network, particularly in poorly vascularized hypoxic 
regions, increase tissue stiffness, providing an additional physical barrier that further 
limits the penetration of anticancer drugs19. These reports suggest the importance of 
research on whole cancer tissue at the molecular level. The endoscope with Raman 
spectroscopy gives us a chance to study intact cancer tissue with repeated non-invasive 
observations during long term chemotherapy. The present study demonstrated the 
feasibility of Raman endoscope in the study of anticancer drugs in situ. 
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ⅠⅠ - 3. Material and Methods 
1. Preparation of the AOM-DSS colorectal cancer model mice 
BALB/cCrSlc mice were purchased from SLC (Shizuoka, Japan). The AOM and 
DSS were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). AOM 
was dissolved in normal saline solution (Otsuka Pharmaceutical Co., Ltd., Tokushima, 
Japan) and a 7.4 mg/kg dose was administered by intraperitoneal injection to each 8-
week-old mouse6. The mice were then fed DSS in drinking water (30 mg/ml) for 1 week 
and this cycle was repeated twice at a 2-week interval. The study was approved by the 
ethics committee of Kwansei Gakuin University. 
 
2. Anticancer drug treatment 
5-FU (LKT Laboratories, Inc., Tokyo Chemical Industry, Tokyo, Japan), 
docetaxel (Tokyo Chemical Industry, Japan), and CDDP (Tokyo Chemical Industry, 
Tokyo, Japan) were the anticancer-drugs used. 5-FU and CDDP were diluted with saline 
in accordance with previous reports20,21. They were administered to the mice at doses of 
25 mg/kg and 1.3 mg/kg for 5-FU and CDDP, respectively. The stock solution of 
docetaxel (50 mg/ml in ethanol) was diluted with polysorbate 80 (Wako Pure Chemical 
Industries, Ltd., Osaka, Japan) and 5% dextrose (Sigma-Aldrich Chemical Co., St. Louis, 
MO, USA) in water (D5W) as described in previous reports22. The prepared solutions 
were administered by intravenous injection 2 weeks after AOM/DSS treatment and 
Raman measurements were then carried out 2 weeks after the anticancer drug treatments. 
Control mouse models were treated with normal saline instead of anticancer drugs. There 
were five 5-FU, three CDDP, three docetaxel treated and two control AOM/DSS mouse 
models prepared. Three of the 5-FU treated models underwent Raman observation before 
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and after the drug treatments. CDDP and docetaxel treated models didn't observed before 
and after treatments. All chemicals used were reagent, not medical, grade. 
 
3. Raman measurements 
 A Raman system equipped with BHRP and a miniaturized endoscope were used 
for in situ Raman measurement in the live mouse colon11,12. The endoscope (Machida 
Endoscope Co. Ltd., Japan) had a 1.2 mm diameter channel for the BHRP, illumination, 
and image fibers, and its total diameter was 2.5 mm. The BHRP had a sapphire ball lens 
500 m in diameter (Edmund Optics, USA) and a hollow optical fiber of 420 m outer 
diameter (Doko Engineering LLC, Japan)9-12. A diode laser (785 nm, Toptica Photonics, 
Germany) was used for excitation. The Raman system included a single polychromatic 
Raman spectrometer (F4.2, focal length 320 mm, 750 nm blazed 600 l/mm grating; 
Photon Design Co. Ltd., Japan) and a charge coupled device detector (DU420-BRDD; 
Andor Technology Co. Ltd., Northern Ireland). The BHRP was coupled to the 
spectrometer through a long-pass filter (LF; Semrock, USA), a notch filter (NF; Kaiser 
 
Fig.2-1 The structure of the miniaturized Raman endoscopic system with a schematic drawing of the 
experimental setup (a); the structure of the head of the endoscope and image of the Raman measurement 
in a colon tumor (b). 
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Optical System, USA), and 2 lenses to focus the laser and Raman scattered light into the 
hollow optical fiber and the slit (100 µm width: ~10 nm of spectral resolution). Schematic 
pictures of the Raman system are depicted in Fig. 2-1. The detailed specifics of the 
instruments have been described elsewhere23. To obtain high quality Raman spectra, the 
laser power was 60 mW and the exposure time was 60 seconds. 
 
4. Procedure for endoscopic observation 
 The mouse was anesthetized using an inhalation anesthesia apparatus (SurgiVet, 
USA) and kept on a warming plate to maintain body temperature23. The concentration of 
isoflurane (Mylan, Tokyo, Japan) was carefully controlled in the range between 1.0 and 
2.5%. The endoscope was inserted into colon through the anus, and then the lumen was 
pressurized with air via the channel to maintain the field of view. Feces that remained in 
the colon were removed by washing with saline. The BHRP was inserted into the 
endoscope’s channel to measure the Raman spectra. The distance of the tumor from the 
anus was recorded through repeated measurements. The detailed procedure for 
observation and measurement has been described previously23. 
  
5. Histology study 
Mice were sacrificed under anesthesia after Raman measurement and the colon 
was resected. The colon tissue was fixed with 10% formaldehyde (Wako Pure Chemical 
Industries, Ltd., Japan) for 24 hours and dehydrated with ethanol. The tissue was sliced 
at 5 µm thickness after paraffin (Sakura Fineteck, Japan) embedding25 and the samples 
were stained with Masson's trichrome stain HT15-1KT kit (Sigma-Aldrich Chemical Co., 
St. Louis, MO, USA) and Mayer's hematoxylin solution (Sigma-Aldrich Chemical Co., 
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St. Louis, MO, USA) for histopathological study. 
 
6. Data analysis 
The Raman spectrum was treated to remove background noise spectra due to the 
Raman probe and the coupling stage. Then, fifth polynomial line fitting was applied 
repeatedly 5 times to remove any fluorescent background. To minimize negative 
composition in the spectrum, only spectral areas with a negative value were subjected to 
the fifth polynomial fitting from the second iteration. The spectral intensity was 
standardized with a phenylalanine band at 1003 cm-1, which was sharp and helped to 
accurately determine the intensity accurately26. Chemometrics software (Unscrambler; 
CAMO, USA) was used for principal component analysis (PCA) and partial least square 
regression discrimination analysis (PLSR-DA)27,28. Spectrum smoothing was applied to 
remove noise using the Savitzky-Golay method (11 points) for the spectra shown in Fig. 
2-3. 
 
ⅠⅠ - 4. Results 
1. Observation of the same tissue before and after drug treatment 
Mice with tumors that were too large were excluded from the study to avoid excess 
contact with the endoscope head. Since large tumor lesions are often vulnerable and easily 
scratched, I was concerned that physical stimulation may affect the characteristics of the 
tumor. The head part of the endoscope can be moved up and down through the use of a 
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lever at its handle. The probe rod is pulled or pushed gently to position the probe head at 
the measuring site. It was possible to reach any point within the lower colon and rectum 
under visual guidance. The detailed handling procedure has been described in our 
previous report22. Several (3–7) tumors were measured in each mouse model. 
First, I investigated the effect of the anticancer drug on the same tumor in the 3 
mouse models. Tumors were observed with the Raman endoscope; the mice were treated 
with the drug for 2 weeks, and then observed again with the Raman endoscope. Pictures 
of a typical colorectal cancer lesion before (A) and after (B) 5-FU treatment are shown in 
Fig. 2-2. No major difference was observed in shape, size, or color in the images. The 
effect of 5-FU cannot be determined by endoscopic observation. Corbett et al. reported 
that 5-FU treated colorectal tumor sizes in mouse are not different only two weeks29. The 
averaged Raman spectra of the tumors before (a; n = 24) and after (b; n = 22) the 5-FU 
treatment collected from the 3 mice, and their different spectra (c) are depicted in Fig. 2-
3. Bands at 1654, 1440, and 1304 cm-1 were assigned to amide I, CH 
 
Fig.2-2 Endoscopic images of a typical colon tumor. An image before anticancer drug treatment (A; 15 
weeks old) and after anticancer drug treatment (B; 17 weeks old). 
A B
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bending, and amide III vibrational modes of the proteins30. Very weak bands appeared in 
the different spectrums (c) so their spectral difference was relatively small in the averaged 
spectra. The weak negative bands at 1742, 1453, 1070, and 843 cm-1 may be attributed to 
fat31,32. 
 The spectra of tumors before and after the 5-FU treatment were analyzed with 
PCA. A score plot for PC2 and PC3 is depicted in Fig. 2-4A. The datasets of these groups 
are clearly classified into two distinct sets, suggesting that molecular alterations occurred 
due to drug treatment. Although data were obtained from 3 mice, no remarkable division 
or grouping was observed in each group for before/after drug treatment. This shows that 
the AOM/DSS treatment induced well-controlled oncogenesis and that this model 
generated homogeneous tumor tissues. The PC1 was strongly related to the presence of 
 
Fig. 2-3 Raman spectra of tumors measured before 
(a; n = 24) and after anticancer drug treatment (b; 
n = 22), and their different spectra (c; (b)–(a)) 
 
Fig. 2-4 A score plot (A) for PC2 and 3 of the 
PCA model built for the datasets of tumor tissue 
before (●; n = 24) and after 5-FU treatment (□; n 
= 22). Loading plots (B) of PC2 (a) and PC3 (b). 
(*: sapphire ball lens, **: oxygen) 
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fat and has no relevance to discrimination 
between the datasets (data not shown). The 
PC2 and 3 contributed almost equally to the 
discrimination. The contributions of PCs 1–
3 were 19%, 11%, and 7%, respectively. 
There was no remarkable information 
included in PCs 4–8 to discriminate these 2 
datasets. The loading plots of PC2 and 3 are 
shown in Fig. 2-4B. They show 
characteristic features in the wave number 
area below 1300 cm-1. Since PCA merely 
extracts components related to the largest 
dispersion in the datasets, it is blind to the 
origin of the component. Because the PCs 
are orthogonal to each other, the loading plot 
of the lower PC is distorted by the higher PC. In the PCA result, a discriminating 
component between the 2 groups is divided into PC2 and PC3. To maximize the difference 
between the two data groups, PLSR-DA is applied. Two dependent variables, “−1” or “1” 
were assigned to the datasets before or after the treatment. Since each dataset was 
weighted according to the dependent variables, the factor in PLSR-DA generally 
represents the strongest contribution able to distinguish 2 datasets. The discrimination 
model was evaluated by the leave-one-out cross-validation method.  
 A score plot for factors 1 and 2 is depicted in Fig. 2-5A. The datasets were 
successfully categorized, particularly due to factor 1. The correlation coefficients for the 
 
Fig. 2-5 A score plot (A) for factors 1 and 2 of 
the PLSR-DA model built for the datasets of 
tumor tissue before (●; n = 24) and after 5-FU 
treatment (□; n = 22). Loading plots (B) of 
factor 1 (a), factor 2 (b), and factor 3 (c). (*: 
sapphire ball lens, **: oxygen). 
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calibration and validation were 0.974 and 0.904, respectively, for the discrimination 
model built with 3 factors. The loading plots of factors 1–3 are shown in Fig. 2-5B and 
represent the largest differences between these two data groups. Although it is noisy, there 
are several positive broad bands near 1654, 1432, 1150, and 725 cm-1 observed in factor 
1.  They seem to correlate with saccharides, DNA, RNA, and some amino acids in the 
tissue33. Factors 2 and 3 seem to reflect changes in protein components. According to a 
previous study, the concentration of collagen I was reduced along with the advancement 
of the tumor24. However, characteristic bands due to collagen were not observed in the 
factors. All data were obtained from the same tumor in the same mouse, and therefore the 
results exclude lesion dependency and mouse dependency but include time dependency; 
there was a 2-week difference between the data acquisitions for with and without 
anticancer drug treatment.  
 
2. Comparison of effects among 3 anticancer drug treatments 
The effects of 5-FU, CDDP, and docetaxel were compared in the same age 
AOM/DSS mouse models. To study the effect of anticancer drugs free from time 
dependency, a separate control mouse model that was the same age as the drug-treated 
model and did not undergo any drug treatment was employed. The Raman spectra are not 
shown here but were very similar to the spectra of the tumor in Fig. 2-3. Since the different 
spectra between the treated and control groups did not provide much useful information, 
the Raman spectra were analyzed with PCA and PLSR-DA. The datasets of the 2 control 
and 5-FU treated 3 mice had separated groups in a score plot for PC1 and PC3. There is 
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no obvious information to distinguish the data groups observed in PCs 2 and 4–8.  As a 
results of analysis only one group for checking individual difference by PCA, the data 
from 5-FU treated 3 mice was not separated in PC1 to PC7 and the data from 2 control 
mice was not separated in PC1 to PC7, too. Intra-category classification was not observed 
  
Fig. 2-6 Score and loading plots of the PLSR-DA model built for tumor lesions without and with 
treatments with 5-FU (A, B), CDDP (C, D), and docetaxel (E, F). Figures A, C, and E represent their 
score plots for control (no treatment; 〇; n = 10), 5-FU (□; n = 32), CDDP (△; n = 26), and docetaxel 
(◇; n = 22). Figure G represent score plots for control (no treatment; ×; n = 8) and control  (no 
treatment; ＊; n = 7). Figures 2-6B, 6D, 6F and 6H are loading plots of their factor 1 (a), factor 2 (b), 
and factor 3 (c). (*: sapphire ball lens, **: oxygen) 
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in both the control and treated datasets, suggesting that there is no characteristic or 
individual difference among the mouse models. The PLSR-DA results are shown in Fig. 
2-6. A score plot for factors 1 and 2 for the datasets of 5-FU treated and control cancer 
mouse models is depicted in Fig. 2-6A. The data groups are categorized into 2 groups 
mainly according to factor 1. Loading plots of factors 1–3 are shown in Fig. 2-6B. The 
correlation coefficients of the discrimination model were 0.982 and 0.851 for the 
calibration and validation for the discrimination model built with 3 factors, respectively. 
Several positive broad bands were observed near 1660, 1439, 1156, and 732 cm-1 in factor 
1, similar to those in factor 1 in Fig. 2-5B.  
Reactions of the tumors to different kinds of anticancer drugs were observed. 
PLSR-DA results for datasets of control and CDDP treated mouse models are shown in 
Fig. 2-6C and 2-6D. The correlation coefficients were 0.975 and 0.765 for the calibration 
and validation for the discrimination model built with 3 factors. The control and treated 
datasets are well discriminated in the score plots for factors 1 and 2 (Fig. 2-6C). These 2 
factors suggest that there are at least 2 independent reactions taking place in the tumor 
tissue due to CDDP administration. Loading plots of factors 1–3 are depicted in Fig. 2-
6D. The spectrum has no apparent features, suggesting that the loading plot reflects minor 
alterations within molecular species, such as lipids and proteins, but not large increases 
or decreases of specific molecules. PLSR-DA results for the datasets corresponding to 
control and docetaxel treated mouse models are depicted in Fig. 2-6E and 2-6F. The 
correlation coefficients of the discrimination model were 0.967 and 0.709 for the 
calibration and validation for the discrimination model built with 3 factors. The control 
and treated datasets are also well discriminated in the score plot for factors 1 and 2 (Fig. 
2-6E). Loading plots of factors 1–3 are depicted in Fig. 2-6F. Bands at 1655, 1435, 1291, 
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and 1269 cm-1 are assigned to C=C 
stretching, CH deformation, CH2 
bending, and C-H bending 
vibrational modes of lipids, 
respectively34-36. The spectral 
features of factors 1 and 2 looks like 
they correspond to fat. There are 
some broad bands observed in the 
lower frequency region that reflect 
differences in hydrocarbon chain 
length. The drug treated data group 
has minus scores in both factors 1 and 
2. In contrast, the loading plots are 
positive for factor 1 but negative for 
factor 2. These facts suggest 
exchanges of fat species for those that 
may have different chain lengths. Lipids may leak out from the cells by apoptosis and be 
reflected in the measurement. PLSR-DA results for the data sets corresponding to control 
and control mouse models are depicted in Fig. 2-6G and 2-6H for negative control. The 
correlation coefficients of the discrimination model were 0.997 and 0.601 for the 
calibration and validation for the discrimination model built with 3 factors. Loading plots 
of factors 1–3 are depicted in Fig. 2-6H. No characteristic band appears in loading plots 
of factor 1-3 in Fig. 2-6H. These facts suggest almost noise factor discriminate controls. 
Raman spectra were collected for non-tumor tissues in the colon of the colorectal 
 
Fig. 2-7 Score and loading plots of the PLSR-DA model 
built for tumors (□; n = 10) and non-tumors (●; n = 18) 
tissues in a control (without any treatment) mouse. A 
score plot (A) for factor 1 and 2 and loading plots (B) of 
factor 1 (a), factor 2 (b), and factor 3 (c). (*: sapphire 
ball lens, **: oxygen) 
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cancer mice models. The PLSR-DA method was applied to discriminate between tumor 
and non-tumor tissues. A score plot for factors 1 and 2 is depicted in Fig. 7A. The 
correlation coefficients were 0.997 and 0.781 for the calibration and validation for the 
discrimination model built with 3 factors. It demonstrates that endoscopic Raman 
spectroscopy is able to distinguish cancer tissue in situ. Loading plots for the factors 1 
and 2 in Fig. 2-7B show characteristic features. In our previous study, a reduction in 
collagen was observed as the cancer advanced in the AOM/DSS colorectal cancer mouse 
model. Negative bands at 859 and 941 cm-1 in the loading plot of factor 1 (a) are 
assignable to hydroxyproline in collagen37. It suggests a reduction of collagen in the 
tumor tissues, in good agreement with our previous study. Bands at 1271, 1307, 1445, 
and 1658 cm-1 in the loading plot of factor 2 (b) are due to triacylglycerol in fat tissue32,33. 
The dispersion for the dataset of non-tumor tissue is larger than that of the tumor tissue. 
The normal colon wall consists of mucosa, muscle, and fat layers, and the thickness of 
the mucosa is not homogenous. In contrast, a polyp is covered with a thick layer of tumor 
cells with mucosal origin38. Because the working distance of the BHRP was 58 µm, the 
variety in collagen and fat concentration reflects the layer structure of the non-tumor 
tissue.  
The effects of the anticancer drugs were examined in the non-tumor tissues. 
Raman spectra of non-tumor tissues were compared with the control and drug treated 
mouse models. Raman spectra of normal and tumor tissues after 5-FU treatment were 
evaluated with the PLSR-DA model built with datasets for normal and tumor tissues 
without drug treatment. The results (not shown) indicated that both the normal and tumor 
datasets were not classified as they should be, suggesting that 5-FU treatment modified 
molecular compositions in such tissues. A score plot of 4 datasets for normal and tumor 
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tissues, with and without 5-FU treatment, is depicted in Fig. 2-8A. The 4 datasets are 
classified into 4 independent categories, indicating that 5-FU affects not only cancer 
tissue but also normal tissue. PCA score plots of datasets for CDDP (B) and docetaxel (C) 
treated samples are also compared in Fig. 2-8. The datasets with drug treatment of normal 
and cancer tissues are similarly categorized in these plots. Previous reports showed that 
the efficacies of CDDP and docetaxel 
treatments were generally lower than 
that of 5-FU treatment for colorectal 
cancers. The present results suggest 
that Raman analysis is able to detect 
infiltration of anticancer drugs to the 
tissues but were not able to evaluate 
their efficacy. I did not suppose this 
result. It is neccesary to investigate 
these anticancer drug effects for 
normal colon tissues of mice without 
AOM/DSS treatment. 
Images of tumor tissues, 
measured Raman spectra and 
analysed in Fig. 2-6, stained with 
Masson's trichrome staining method 
are shown in Fig. 2-9. It colors stromal 
tissue that is generally rich in collagen 
I in blue and keratin in red.39 The 
 
Fig. 2-8 Score plots of PCA models built with datasets 
of non-tumor and tumor tissues with and without drug 
treatments. Datasets of tumor lesions and non-tumor 
tissue of a control mouse are marked with ◇ and 〇; 
those of tumor lesions and non-tumor tissue with drug 
treatment are marked with □ and △, respectively. 
Anticancer drugs are 5-FU (A), CDDP (B) and 
docetaxel (C) 
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concentration of collagen reduces in advancing cancer, as observed in our previous 
study23. As such, I expected an increase in collagen in the anticancer drug-treated tissues. 
An image of cancer tissue treated with 5-FU (A) seems to have more green coloring 
compared with that of non-treated tissue (D). Images showing tissue treated with CDDP 
(B) and docetaxel (C) seem to have slightly higher blue components than non-treated 
tissue (D). This may indicate the efficacy of the anticancer drugs, but is difficult to come 
to any concrete conclusion. This pathological tissues was fixed with formaldehyde before 
analysis. It was not able to dye the lipid.  
 
ⅠⅠ - 5. Discussion 
 
Fig. 2-9 Microscopic images of Masson's trichrome stained colorectal tumor tissues occurred in the 
lumen from the mucosal epithelium; treated with 5-FU (A), CDDP (B), docetaxel (C) and no treatment 
(D). 
A B
C D
100μm 100μm
100μm 100μm
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It is possible to study changes in 
the extracellular matrix and in cells 
using animal models, which cannot be 
achieved in experiments with cultured 
cells. In cancer tissues, it is especially 
important to observe variations in the 
density of collagen species. Although a 
doctor often prescribes multiple 
anticancer drugs for enhanced 
therapeutic benefit in real-life cancer therapy, reaction to a single drug is observed in the 
present study, making the results as simple to interpret as possible. Hence, the present 
animal study with mouse-sized Raman endoscopy is valuable. The results strongly 
indicate that Raman endoscopy was able to detect molecular changes induced by 
anticancer drugs in tumor tissue in situ. 
The reduction of collagen species was observed in the cancer lesion, which was 
also observed in our previous study23. Although I expected increased collagen in the 5-
FU treated cancer lesion, the molecular changes observed were instead attributed to 
changes in saccharides, DNA, RNA, and some amino acids. However, the endoscopic 
observations were performed after 2 weeks of drug treatment. This may be too early to 
expect to observe clear therapeutic effects in the tissue. In subcutaneous mouse models 
of DLD-1 (a human colon adenocarcinoma cell line), the tumor size was reduced 5 days 
after anticancer drug treatments with 5-FU and docetaxel (Fig. 2-10; no data for CDDP). 
Although those cancer cells are not the same as in the present spontaneous cancer model, 
it may be assumed that anticancer drugs will show efficacy in cancer tissues 2 weeks 
 
Fig.2-10 Tumor size in subcutaneous 
mouse models of DLD-1 (human colon 
adenocarcinoma cell line). Anticancer 
drugs, 5-FU and docetaxel, were 
administered at day 21.  
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following the initiation of therapy, at the molecular level at least. Although I refer to the 
surrounding tissue as “normal tissue,” it seems to be affected by inflammation induced 
by DSS administration. DSS causes diarrhea in the mouse model, which results in 
regeneration of endothelial cells. Since one of the mechanisms of 5-FU is interfering with 
DNA reproduction to induce apoptosis prior to cell division, 5-FU possibly induces 
inflammation in normal tissues as well as tumor cells.  
The PLSR-DA results indicated that the 5-FU treated group had alterations in 
DNA, RNA, and amino acid composition. Because 5-FU is an analog of uracil as well as 
a disrupter of TS, it interferes with both DNA and RNA synthesis13. In contrast, the PLSR-
DA suggested that the CDDP treated group had alterations in fat and protein species. 
CDDP builds cross-links between DNA strands in the double chain and blocks DNA 
duplication to induce apoptosis14. The results for the docetaxel treated tumors indicated 
increased fat concentration in the tissue. Docetaxel stabilizes tubulin to intercept the last 
stage of mitosis and induces apoptosis15.  
These 3 anticancer drugs, although having different mechanisms, showed 
characteristic spectral changes, suggesting that this technique is able to determine the type 
of cellular reaction induced in live cells within cancer lesions. The histopathological 
observation shows typical images of cancer tissue and stromal tissue was increased 
especially in 5-FU treatment. In contrast, the datasets of cancer tissues with and without 
drug treatment showed quite clear differences in the score plots and discrimination 
models. The spatial resolution of the present BHRP is estimated to be ~100 µm and the 
Raman spectrum represents the averaged molecular composition in the excitation volume, 
~106 µm3. The results of Raman data was not similar in MT staining in Fig.2-9. It is 
necessary to measure the deeper area by changing the material of the ball lens which is 
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much longer working distance in BHRP and to evaluate anticancer drug effects. 
 
ⅠⅠ - 6. Conclusion 
 Raman endoscopy has strong potential to detect effects of drug treatment in the 
digestive tract before the appearance of morphological changes. The Raman observation 
in situ showed a lower density of collagen species in cancer tissue, which is a good marker 
for discrimination of cancer lesions from normal tissue. Increased collagen should not be 
observed in the drug treated cancer lesions after 2 weeks of therapy. Molecular changes 
were observed but they were not specific to the cancer tissue. The discrimination model 
for cancer tissue is not valid to analyze the datasets of cancer and normal tissues with 
drug treatment, suggesting that the drug effects both normal and cancer tissues. It is 
difficult to determine drug efficacy from histopathological observation by the 
inexperienced observer. In contrast, Raman analysis is able to achieve this with BHRP 
and multivariate analysis, without any assessment by an experienced person. The present 
results demonstrate the potential of Raman endoscopy in the study of anticancer drug 
therapy. Raman analysis is highly sensitive to the effect of anticancer drugs. It is, however, 
necessary to conduct further detailed research to determine the therapeutic effect induced 
by anticancer drugs.
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ⅠⅠⅠ - 1. Abstract 
The site dependency in cancer tissue was evaluated using unstained 
autofluorescence hyperspectral imaging and Raman spectroscopy. The autofluorescence 
image reflected the distribution of the intact fluorescence materials such as nicotinamide 
adenine dinucleotide (NADH), flavin adenine dinucleotide (FAD), and collagen in the 
live subcutaneous tumor mouse model. Raman spectroscopy revealed the difference in 
blood flow between the active and non-active areas by NADH imaging. The 
autofluorescence image in situ and Raman image showed the distribution of type I 
collagen. The autofluorescence image in situ gathered information that was inaccessible 
from the tissue section of the sample. The combination of autofluorescence imaging and 
Raman spectroscopy may reflect the site dependency in cancer tissues.  
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ⅠⅠⅠ - 2. Introduction 
 The purpose of this study was to establish a noninvasive imaging technique for 
the in situ cancer diagnosis from cancer tissues. Histopathology, the gold standard for 
cancer diagnosis, allows decision-making based on visual observation. It is a type of 
pattern recognition procedure that discriminates between cancerous and normal tissues. 
The diagnosis of colorectal cancer is based on image observations, and mainly includes 
endoscopic observation, X-ray computed tomography (CT), magnetic resonance imaging 
(MRI), positron emission tomography (PET), and histopathology1-5. Images in Raman 
spectroscopy are obtained for the same purpose. The conventional imaging techniques 
allow visualization of tissue morphology but fail to reveal molecular information. In 
contrast, previous Raman studies suggest that the molecular composition of tissues is 
reflective of the development of cancer and the effects of anticancer agents6,7. Feofanov 
et al. reported confocal Raman microspectroscopy and imaging study of live cancer cells8. 
Zabaleta et al. reported imaging with surface-enhanced Raman scattering (SERS) 
nanotags in a live mouse9. Cancer tissue in general exhibits low uniformity and complex 
structures comprising differentiated tissue parts10. The excitation volume of general 
Raman instruments is quite small; for instance, it is 1 × 1 × 5 µm for a Raman microscope 
with a ×60 objective lens. As cancer tissue exhibits microstructure, its Raman spectrum 
may probably display site dependency. It may be difficult to collect information 
representing the whole lesion of the cancer tissue in a spot measurement. To acquire 
Raman images, a Raman microscope system with a raster scanning sample stage is 
commercially available. Raman images show molecular information without staining11. 
Many researchers are making efforts to develop an analytical method to extract molecular 
information from Raman images.  
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As Raman images are acquired Raman spectra from each point, the measurement 
may take several hours. It is necessary to use a sample fixed under a microscope. Raman 
image measurement is difficult to perform in situ using an endoscope. Other 
measurements are required to collect images of colorectal tumors in situ without surgery 
or staining. Autofluorescence has been studied for biomedical samples, especially for 
tissue analysis without staining or labeling. Autofluorescence is attributed to nicotinamide 
adenine dinucleotide (NADH) and flavin in viable cells and elastin and collagen from the 
extracellular matrices12,13. The maximum absorption and emission wavelengths for 
typical autofluorescence materials in tissues are well-studied14-18. Uedo et al reported the 
use of an autofluorescence image for the determination of colorectal tumors in situ with 
an endoscope19.  
During the acquisition of Raman spectral image by lateral scan, a spectrum is 
measured at each spot and the image comprises numerous measuring points, wherein each 
point has a total spectrum. Such an image consisting of spectra is referred to as a 
“hyperspectral image.” Sato laboratory has a system that allows autofluorescence 
hyperspectral imaging (AF-HSI), and comprises an illumination part that emits 
monochromatic light in a tunable range from 250 to 800 nm, a detection part that produces 
an image in a tunable range from 400 to 1000 nm, and a hand-held probe connected to 
the detection part with an optical fiber. The AF-HSI system automatically collects images 
with different excitation and collection wavelengths. The detection part is equipped with 
band-pass filters and a highly sensitive charge-coupled device (CCD) camera. The full 
range of 250−800 nm excitation and 400−1000 nm detection may be measured in 600 s. 
Autofluorescence techniques have been applied for medical observations20-22. Diagnosis 
by autofluorescence and image measurement by Raman spectroscopy is studied. Kong et 
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al. reported that the basal cell carcinoma was discriminated ex vivo with 100% sensitivity 
and 92% specificity using autofluorescence and Raman imaging23. In contrast, the 
conventional Raman imaging system needs more than several hours to obtain Raman-
HSI, owing to raster scanning. Reports suggest that SERS images were obtained from the 
living body with the delivery of nanoparticles into tissues7,24. With AF-HSI imaging, it is 
possible to obtain information on the tumor shape from the living body in a short period 
of time.  
Here, the potential application of the AF-HSI system and Raman spectroscopy to evaluate 
colorectal tumors was investigated. The combination of AF-HSI images and Raman 
spectra was used at several points representing characteristic tissue types to study the 
relationship between fluorescence and Raman spectra at various microsites in the cancer 
tissue. The low uniformity of cancerous tissues may pose difficulty in comparison of the 
structure of cancer tissues in the absence of any information on the localization of the 
active cell division site. NADH and flavin adenine dinucleotide (FAD) are reportedly used 
to indicate cell viability. It is possible to identify the sites of active cell division in the 
cancer tissue by observing NADH. I examined the localization of NADH and collagen in 
the cancer tissue and decided to observe the composition differences by Raman 
spectroscopy. To evaluate AF-HSI, Raman images were obtained for the same tumor 
sample that was fixed and the results were compared with those of AF-HSI. A 
subcutaneous tumor mouse model was used for the study. 
 
ⅠⅠⅠ - 3. Material and Methods 
1. Preparation of DLD-1 subcutaneous cancer mouse model 
BALB/c slc-nu/nu nude mice were purchased from SLC (Shizuoka, Japan). 
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DLD-1, a colorectal adenocarcinoma cell line, was implanted under the skin at the femur 
of 4-week-old mice at 1 × 106 cells/mL density in 0.1 mL normal saline. After 3 weeks, 
the tumor size was about 5 mm in diameter. The tumor was surgically exposed under 
anesthesia treatment by removing skin and cutting a part to observe the inside of the tissue. 
AF-HSI and Raman measurements were performed on the live tissue. The mouse was 
anesthetized using isoflurane (Wako Pure Chemical Industries, Ltd., Japan) and kept on 
a warming plate to maintain the body temperature to about 37°C. The animal procedure 
was approved by the ethics committee of Kwansei Gakuin University. 
 
2. Autofluorescence hyperspectral imaging system 
The schematic representation of AF-HSI system is provided in Fig. 3-1. The light 
  
Fig.3-1 The structure of AF-HSI System. Illumination was 250-800 nm by monochromater and mercury 
xenon lamp. Collection was 400-1000 nm by band pass filter unit and CCD detector. Measuring sample 
was in block box to shut out lights from outside. Tumor was operated flat surgery. 
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source was a mercury xenon lamp (500 W, L8288, Hamamatsu Photonics, Japan). The 
light was filtered and selected by a monochromator in a wavelength ranging from 250 to 
800 nm by 10 nm of spectral resolution. The excitation light was transferred by an optical 
fiber to the hand-held probe. The collected by the prove was transferred into the detection 
unit by a bundled image filter light the image passed through a bandpass filter. The image 
of the specified wavelength was detected by a CCD (iXON DV887ECS-BV, Andor 
Technology Co. Ltd., Northern Ireland) with 512 × 512 pixels. The temperature of CCD 
was −68°C. The detection unit had 15 BP filters from 400 to 1000 nm with 40 nm step. 
The acquisition time was 1 s for each image. The measurement was performed by 
attaching the window of the probe head onto the sample. The measurable area of the probe 
was 5 × 5 mm. 
 
3. Raman measurement 
A Raman system equipped with BHRP was used for in situ Raman measurement 
in live mouse tumors. A diode laser (785 nm) was used for excitation. The laser power 
was 60 mW at the sample point. The Raman system used was the same mentioned in 
Chapter I and II. Raman spectra of subcutaneous tumors were collected at several points 
selected according to AF-HSI.  
 
4. Raman imaging 
The tumor tissue was fixed with 10% formaldehyde (Wako Pure Chemical 
Industries, Ltd., Osaka, Japan) for 24 h, dehydrated with ethanol, and subjected to 
paraffinization (Sakura Finetek, Tokyo, Japan). The paraffin-embedded tissue was sliced 
into 20-µm-thick pieces, and placed on a glass substrate. Paraffin was removed by xylene 
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and ethanol before measurement. Raman images were collected by Raman image system 
(inVia 417A48 Renishaw, UK). The laser wavelength was set at 532 nm and the exposure 
time was 10 s at each measured point. The sampling interval of the imaging was 100 µm, 
and the scanned area was 5000 µm × 5000 µm, including 2500 sampling points. HSI was 
analyzed by Wire software (Renishaw, UK). 
 
5. Histopathological study 
The resected whole tumor specimen was immediately fixed with 4% 
paraformaldehyde at 4°C, and dehydrated through a graded series of ethanol (70%, 80%, 
90%, 95%, and 100%). The specimen was immersed in histo-clear and embedded in 
paraffin. Sections (5 µm thick) were prepared and stained with hematoxylin–eosin (H/E) 
or Masson's trichrome stain using HT15-1KT kit (Sigma-Aldrich Chemical Co., St. Louis, 
MO, USA) for histopathological study. 
 
6. Data analysis 
The image data obtained using AF-HSI were exported as a special file type, 
wherein the intensity measured at each excitation and detection wavelength was recorded 
as a binary value at each pixel. A homemade program made on Igor platform 
(WaveMetrics, US) was used to retrieve the image at a specific combination of 
wavelengths. A program was built to analyze the fluorescence image dataset that allowed 
the creation of a fluorescence image plot to be displayed in the image. Raman spectrum 
was treated repeatedly for five times to remove background noise using fifth polynomial 
line fitting. The spectral intensity was standardized with a phenylalanine band at 1003 
cm−1. Chemometrics software (Unscrambler; CAMO, USA) was used for principal 
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component analysis (PCA). 
 
III - 4. Results  
A subcutaneous tumor was grown in the femur of the mouse to a size of 
0.06−0.12 cm3. AF- and bright-field images of the tumor in situ are depicted in Fig. 3-2 
(A-D), respectively. The image was obtained at 340 nm excitation and 460 nm collection 
wavelengths suitable for fluorescence. Image (B) was obtained with 450 nm excitation 
and 500 nm collection wavelengths suitable for FAD imaging. Image (C) was obtained 
using 450 nm excitation and 540 nm collection wavelengths suitable for collagen. NADH 
  
Fig. 3-2 AF- images of live tumor tissue and that of bright one. The topographies in A-C represent 
concentration of NADH (A), FAD (B) and collagen (C) respectively. The bright field image was 
collected at the same point where the AF-HSI was obtained. 
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and FAD exhibited almost the same localization in (A) and (B). Collagen had a larger 
area than NADH and FAD in (C). AF-HSI revealed the localization of NADH, FAD, and 
collagen in live cancer tissues. The distribution of autofluorescence from NADH (A) and 
collagen (C) was different within the same tumor. NADH is known as an indicator of cell 
viability, and collagen is a major component of the extracellular matrix. Fig. 3-2 (D) 
shows no difference between NADH active and non-active sites. AF-HSI provided a clear 
image reflective of the structure of the live tissue without any labeling. 
Raman spectra of the tumor model are shown in Fig. 3-3. The spectrum (a) was 
obtained at an NADH active site that displayed strong signals, owing to NADH in the 
AF-HSI image in Fig. 3-2 (A). Cancer cells have higher NADH levels than normal cells, 
owing to their glycolysis25. It is assumed that the NADH active site is dominated by all 
proliferating cells, especially in the cancer tissue. Spectrum (b) was obtained at NADH 
non-active site. The spectrum 
obtained from the subtraction of (b) 
from (a) is depicted in Fig 3-3 (c). 
These bands are assigned to amide 
I (1654 cm−1), CH deformation 
(1304 and 1440 cm−1), amide III 
vibrational modes (1263 cm−1) and 
a respiratory mode phenyl group 
(1003 cm−1)26. In the difference 
spectrum (c), a sharp peak was 
observed at 1435 cm−1 in the 
positive direction, attributable to 
  
Fig. 3-3 Raman spectrum of NADH in the tumor model 
tissue shown active place and (b) is from NADH non-
active place in fig.2. (c) is subtracted spectra of (a) – 
(b). (* is oxygen from BHRP) Characteristic bands due 
to proteins which are rich in tissue are observed at 
1654, 1440, 1304, 1263 and 1003 cm-1. 
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the CH3 deformation mode of alkyl chains of lipid with relatively long chains27. Bands 
corresponding to the heme group in hemoglobin were observed at 1620 cm−1 28. Negative 
bands at 858 and 933 cm−1 corresponded to collagen. Subtracted spectra of active and 
non-active site showed differences in lipid, blood, and collagen concentrations. Raman 
spectra of NADH active and non-active sites were clearly different. It was difficult to 
observe the structure of the tissue without any staining under the bright field. 
Fig. 3-4 depicts the PCA score plot (A) and loading plots of PCs. PCA was 
applied to the datasets of NADH active and non-active sites. The contribution of PC1 was 
51%, much higher than that of PC-2 (18%). PC-1 loading was almost the same as that 
observed from the subtraction spectra of Fig. 3-3 (c). The dataset of NADH active sites 
was well discriminated from that of NADH non-active sites, especially by PC1. In the 
loading plot of PC1, a strong band appeared in the positive direction at 997 cm−1 and was 
attributable to the CO single bond in monosaccharides29. The band at about 1122 cm−1 
corresponded to C-O-C symmetric oscillation of polysaccharides30. The band associated 
with deoxyribose was observed at 1424 cm−1 in the positive direction31. Bands at 1214, 
  
Fig.3-4 (A) is score plot of principal component analysis of Raman spectra obtained from DLD-1 tumor.
■ is from the part (a), ○ is the spectrum from the part (b) in Fig.3. (B) is loading plot of principal 
component analysis of Raman spectra obtained from DLD-1 tumor. (a) shows PC1, and (b) shows PC2. 
(* is oxygen from BHRP) 
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1600, and 1620 cm-1 were probably related to the heme group in hemoglobin. PCA results 
showed that NADH active sites in the tumor were richer in saccharides, deoxyribose, and 
hemoglobin than the non-active sites.  
The AF image (A) reflected collagen I measured at 450 nm excitation and 540 
nm detection wavelengths in Fig. 3-5. Raman images of the resected cancer tissue were 
compared to AF-HSI images. The Raman image of (B) reflected the intensity of Raman 
band at 858 cm−1 for collagen I, whereas the image of (C) was associated with the 
intensity of a band at 1654 cm−1 for proteins. The collagen I distribution in these images 
was different. Masson’s trichrome staining in (D) showed collagen-like stromal tissues 
that stained blue. These tissues were rich in collagen. HE and Masson’s trichrome staining 
  
Fig. 3-5 (A) is AF- image of collagen I. (B) is collagen Raman image using 858 cm-1 Raman band 
intensity. (C) is protein Raman image using 1654 cm-1  Raman band intensity. (D) is Masson's 
trichrome staining of same place. 
 
Fig. 3-6 A and B are picture of HE staining of DLD-1 tumor. C is picture of Masson's trichrome 
staining of DLD-1 tumor. A is observed a part where cells are densely collected or a part where fibrosis 
is progressed. B is the state of the connective tissue can be observed. C is observed stromal tissue that 
was stained blue. 
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images of the tumor tissue observed with Raman imaging and AF-HSI in Fig. 3-5 are 
depicted in Fig. 3-6. In (A), cells are densely packed in a space surrounded by fibrosis. In 
(B), the tissue is dominated by connective tissues and very few cells could be seen. In 
Masson’s trichrome-stained image (C), the stromal tissue was stained blue, indicating that 
the stromal tissue was rich in collagen. HE-stained images of tumors showed varied 
distribution patterns within the same tumor (Fig. 3-6). As both NADH and FAD have a 
similar coenzyme for oxidoreductase, the AF-HSI image of NADH was similar to that of 
FAD. 
 
III - 5. Discussion  
The results of PCA described in Fig. 3-4 suggest that AF-HSI and Raman 
spectroscopy have the potential to identify the region involved in cancer cell division. It 
has been confirmed that NADH active sites exhibited more saccharides, deoxyribose, and 
hemoglobin than non-active sites. Cancer tissues consume a large amount of glucose to 
facilitate repetitive cell division through angiogenesis10,25. From these facts, NADH 
active site was thought to be the region involved in the angiogenesis and cell division. 
NADH Raman band appeared at 1546, 1557, 1620, and 1676 cm−1 32,33. However, these 
results showed a few typical NADH bands, given that Raman spectroscopy collects 
several types of molecules, proteins, lipids, and blood other than NADH. AF-HSI was a 
good guide to distinguish between NADH active and non-active sites in the live tissue to 
perform studies with Raman spectroscopy.  
Both AF-HSI and Raman images described in Fig. 3-5 reveal the difference in 
the localization of collagen I. As the AF-HSI image was acquired from the living body, 
the autofluorescence information was acquired from deeper tissues as against the data 
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obtained from the 20-μm tissue section in Raman images. The comparison between the 
Raman images for collagen I and proteins indicate the relatively correct localization of 
collagen I in Raman images. A Raman band of 858 cm−1 was used for imaging, as this 
band was a better representative of collagen I than the band at 933 cm−1. A Raman image 
of proteins using 1654 cm−1 showed localization of all proteins, including collagen. 
However, images with a single band have low confidence. It is necessary to prepare a 
program to describe more confirmed images using multiple bands. 
 
 
III - 6. Conclusion 
In this study, AF-HSI images were successfully obtained for live tumor tissues. 
Raman analysis revealed higher blood flow rate in the NADH active site than in the non-
active site in tumors. The distributions of collagen observed by Raman imaging was 
different from that detected using AF-HSI. AF-HSI images with a single excitation and 
detection wavelength were acquired in a second. This study demonstrates the potential of 
the HSI system and AF-HSI in the study of colorectal tumors to enable structure 
differentiation in cancer tissues. The combination of autofluorescence imaging and 
Raman spectroscopy has potential applications for in situ cancer diagnosis. 
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General Conclusion 
Improvement in the accuracy of endoscopic technology is desirable for the 
accurate diagnosis of colorectal cancer. Here, Raman spectroscopy was used to support 
endoscopic diagnosis in a mouse model. The first study demonstrates that the mRE 
system and BHRP were able to measure colorectal tumors in the mouse model in situ. 
The advancement in colorectal tumor growth was simultaneously monitored to obtain 
spectral changes and visual information about the decrease in collagen I in the same tumor 
of a live mouse over several weeks of observation. In this study, I observed shrinking 
tumor and I collected Raman spectra from this tumor continuously. LDA results judged 
that this shrinking tumor was still colorectal tumor. The mRE system has potential 
applications in cancer diagnosis without morphological discrimination and Raman 
spectroscopy may serve as a supporting technique to improve the accuracy of endoscopic 
diagnosis. The second study demonstrates the potential of the mRE system with BHRP in 
the study of the effects of anticancer drugs. The effects of anticancer drugs on colorectal 
tumors were monitored using the mRE system. The mRE system is a powerful instrument 
that allowed monitoring of changes in the tumor morphology following drug treatment. 
Raman spectroscopy may be used to confirm the therapeutic effects of drugs and 
determine the left-over cancer tissue, if any, after tumor treatment. In addition, the mRE 
system and mouse model may be used to evaluate the effects of the drug through direct 
observation of colorectal tumors in situ. The third study demonstrates the collection of 
autofluorescence images from cancer tumors in situ and its application for the detection 
of active points in tumors. Raman spectroscopy showed the site dependency of colorectal 
tumors. Although the result revealed the relationship between the AF-HSI and Raman 
images, confirmatory studies are needed. AF-HSI images may be useful to observe the 
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site dependency of colorectal tumors.  
The measurement method using a mouse model, Raman spectroscopy, and AF-
HSI imaging may serve as an important tool in fundamental research to study cancer 
progression and effects of anticancer drugs. It is possible to create an analytical model 
based on the progression of cancer, and Raman spectroscopy may be established as a 
supporting technology for the endoscopic diagnosis of cancers. 
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